PMID: 7029838Jun 1, 1981Paper

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months

Tubercle

Abstract

In a study in Singapore, Chinese, Malay and Indian patients with pulmonary tuberculosis received 2 months of daily treatment with streptomycin, isoniazid, rifampicin, and pyrazinamide followed by daily isoniazid, and rifampicin either with pyrazinamide (SHRZ/HRZ) or without it (SHRZ/HR), allocated at random. Both regimens were given for either 6 or 4 months by random allocation. All 330 patients with drug-sensitive tubercle bacilli pretreatment had a favourable bacteriological response during chemotherapy. After chemotherapy none of 78 SHRZ/HRZ patients and only 2 of 80 SHRZ/HR patients treated for 6 months relapsed bacteriologically, but 9 (11%) of 79 SHRZ/HRZ and 6 (8%) of 77 SHRZ/HR patients treated for 4 months relapsed. Of 33 patients with bacilli resistant to isoniazid, streptomycin, or both drugs pretreatment, only 1 had an unfavourable response during chemotherapy; none of 9 patients treated for 6 months and 2 of 22 treated for 4 months relapsed bacteriologically after stopping chemotherapy.

Citations

May 15, 2012·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·S Rajasekaran, Gaurav Khandelwal
Aug 31, 2007·The Journal of Infectious Diseases·Philip Chukwuka OnyebujohChristopher Curtis Whalen
Jul 11, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ekaterina V KurbatovaJ Peter Cegielski
Apr 10, 1999·AIDS·A L PozniakL P Ormerod
Jun 6, 2012·Antimicrobial Agents and Chemotherapy·Ian M RosenthalEric L Nuermberger
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·G P MorlockR C Cooksey
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·Tsi-Shu HuangYung-Ching Liu
Dec 2, 2011·Journal of Pregnancy·Olabisi M Loto, Ibraheem Awowole
Apr 1, 1989·The American Review of Respiratory Disease·A E BrownH K Webster
Nov 1, 1989·The American Review of Respiratory Disease·H F LecoeurJ H Grosset
Jan 1, 1990·The American Review of Respiratory Disease·L B Heifets, P J Lindholm-Levy
May 1, 1992·The American Review of Respiratory Disease·L Heifets, P Lindholm-Levy
Feb 18, 2003·American Journal of Respiratory and Critical Care Medicine·Henry M BlumbergUNKNOWN American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society
Aug 13, 2004·American Journal of Respiratory and Critical Care Medicine·Eric L NuermbergerJacques H Grosset
Jun 23, 2009·American Journal of Respiratory and Critical Care Medicine·John L JohnsonW Henry Boom
Mar 9, 2010·American Journal of Respiratory and Critical Care Medicine·Charles L Daley
Dec 1, 1990·American Journal of Public Health·C M Nolan
Dec 1, 1990·American Journal of Public Health·G GridleyW J Blot
Mar 24, 2011·Future Medicinal Chemistry·Patrick P J Phillips, Andrew J Nunn
May 23, 2014·Drugs·Abdullah Alsultan, Charles A Peloquin
Sep 10, 2014·The New England Journal of Medicine·Stephen H GillespieUNKNOWN REMoxTB Consortium
Oct 1, 1988·Chest·M A Steele, R M Des Prez
Jun 1, 1987·Tubercle·S Grzybowski
Jul 1, 1991·Respiratory Medicine·L P OrmerodN Horsfield
Jul 1, 1986·British Journal of Diseases of the Chest·V K ChatterjeeM Green
Apr 1, 1996·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·H L Rieder
Feb 1, 1995·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·L P OrmerodN Horsfield
Sep 1, 1985·Journal of Clinical and Hospital Pharmacy·S R SmithR A Stockley
Aug 16, 2005·Health Policy·Christian AuerMitchell G Weiss
Mar 13, 2003·Tropical Medicine & International Health : TM & IH·M BiotJ D H Porter
Nov 23, 2006·Respiratory Medicine·Cesare Saltini
Feb 2, 1999·Respiratory Medicine·A J SimpsonA G Leitch
May 18, 2016·AIDS Research and Therapy·Weerawat ManosuthiSomnuek Sungkanuparph
Jan 1, 1992·Tijdschrift voor economische en sociale geografie = Journal of economic and social geography = Revue de géographie économique et humaine = Zeitschrift für ökonomische und soziale Geographie = Revista de geografía económica y social·L Van Grunsven

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.